Cyteir Therapeutics is using the principle of synthetic lethality to develop cancer therapies. Synthetic lethality is a mechanism used to exploit weaknesses in cancer cells that are not present in healthy cells - drug treatment therefore kills the cancer cell while having minimal impact on surrounding healthy tissue. Cyteir has used this approach to develop their lead candidate, CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. By combining treatment with capecitabine and gemcitabine, Cyteir is currently testing CYT-0851 in a Phase ½ trial in patients with advanced ovarian cancer.

Cyteir Therapeutics

Founded: 2012
Location: Lexington, MA
Employee range: 11 - 50
Funding: $133M IPO Jun 2021; $80M C Feb 2021; $40M B Oct 2019; $29M Mar 2018; $5.5M A Nov 2015

Short description:

Drug notes:

Long description:

Jobs: